期刊文献+

卵巢癌的一线化疗 被引量:2

下载PDF
导出
摘要 在女性生殖器肿瘤中卵巢癌的发生率居第3位,但死亡率居首位。目前,晚期卵巢癌的治疗方法主要为细胞减灭术及术后化疗。研究表明。卵巢癌化疗可延长患者生存期,甚至较单纯手术延长6~7倍。因此化疗在卵巢癌中的价值已得到充分肯定。该癌一线化疗有效率(RR)能达到60%~80%,但是,其中仍有55%~75%的患者于治疗后1~2年内复发,5年生存率很低,如何提高卵巢癌患者的生存率是妇科肿瘤医生当前面临的最大难题。满意的卵巢肿瘤细胞减灭术(Optimal surgical cytoreduction,)是治疗成功的关键,术后辅以化疗可提高卵巢癌患者5年生存率;有效、及时、足量及规范的化疗则是卵巢癌术后至关重要的辅助治疗,不同组织类型的卵巢恶性肿瘤应根据其对化疗药物的敏感性选择不同的化疗方案。
作者 莫秀瑛 李力
出处 《中国医学文摘(肿瘤学)》 2006年第1期88-90,共3页 Journal of Chinese Medical Abstracts·Oncology
  • 相关文献

参考文献11

  • 1沈铿,李孟达,丰有吉,马丁,李子庭,谢辛,孔北华,崔恒,宋垒,彭芝兰,李力,吴鸣,陈亦乐,刘继红,吴令英,郎景和,中国妇科肿瘤学组.泰素周疗和三周疗法作为卵巢癌一线化疗的多中心对照研究[J].中华医学杂志,2005,85(30):2099-2103. 被引量:16
  • 2Martine JP,Kamma B,Keith J.Randomized intergroup trial of cisplatinpaclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer:three-year results[].J of the National Cancer Institute.2000
  • 3The International Collaborative Ovarian Neoplasm (ICON) Group.Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide,doxorubicin,and cisplatin in women with ovarian cancer:the ICON3 randomised trial[].The Lancet.2002
  • 4Deplanque G,Goupil A,Fabbro M,et al.Phase Ⅱ trial of oxaliplatin (OXA) combined with paclitaxel (P) as first-line chemotherapy for patients (pts) with advanced ovarian cancer (AOC):Preliminary results[].Journal of Clinical Oncology.2004
  • 5Hogberg T,Glimelius B,Nygren P,et al.A systematic overview of chemotherapy effects in ovarian cancer[].Acta Oncologica.2001
  • 6Mcgwire WP,Hoskins WJ,Brady MF,et al.Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer[].New England Journal of Homeopathy.1996
  • 7Muggia FM,Braly PS,Brady MF,et al.Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study[].Journal of Clinical Oncology.2000
  • 8Markman M,Liu PY,Wilczynski S,et al.Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial[].Journal of Clinical Oncology.2003
  • 9Alberts DS,Liu PY,Hannigan EV,et al.Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer[].New England Journal of Medicine The.1996
  • 10Martin Gore,Wim ten Bokkel Huinink,James Carmichael,et al.Clinical Evidence for Topotecan-Paclitaxel Non-Cross-Resistance in Ovarian Cancer[].Journal of Clinical Oncology.2001

二级参考文献7

  • 1McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide compared with paclitaxel and cisplatin in patients with stage Ⅲ and Ⅳ ovarian cancer. N Engl J Med, 1996, 334: 1-6.
  • 2Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Nat Cancer Inst, 2000,92 : 699-708.
  • 3The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2. 2triaL Lancet, 2003,361:2099-2106.
  • 4Fennelly D, Aghajanian C, Shapiro F, et aL Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol, 1997,15: 187-192.
  • 5Markman M, Hall J, Spitz D, et aL Phase H trial of weekly singleagent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol, 2002,20:2365-2369.
  • 6Ozols RF, Bundy BN, Greer BE, et aL Phase Ⅲ trial of carboplatin and paclitaxel compared with cisphtin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol, 2003,21 : 3194-3200.
  • 7Bois A du, Luck HI, Meier W. et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Nail Cancer Inst, 2003,95: 1320-1330.

共引文献15

同被引文献15

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部